Replies to post #100029 on Biotech Values

[mcbio]

Re: IDX184 (creatinine)

I’m not aware of a creatinine problem with IDX184. Among the places I looked was the poster presentation on IDX184 pharmacokinetics at EASL 2009:

www.idenix.com/hepc/drug/IDX184_Poster_(handout)_FInal_EASL09.pdf

My guess is that the analyst who asked about creatinine on the 2Q10 CC (Brian Abrahams of Oppenheimer) was merely being thorough, knowing that creatinine was a potential problem area insofar as IDX184 is excreted renally.

Thanks for the response Dew. My concern isn't so much with the analyst, but with the exact language used by IDIX (don't recall who the speaker was, but I know it wasn't J.P.). I know that the quote I used in #msg-52668789 is exactly what was said as I went back and listened a few times to be sure. The reference to "no further creatinine elevations" still bugs me a bit, although it's possible either the speaker just misspoke or I took his language out of context. If there truly were creatinine elevations, one would think those would have been disclosed in the prior PR discussing the Phase 2a results (#msg-49096739 ), unless something occurred after that was not disclosed.

On this topic, 'go seek' indicated to me in private that the subject of creatinine elevations was discussed during some prior call but was deemed not to be related to IDX184. Go seek: inasmuch as the prior calls are no longer accessible, can you add some additional detail to identify during which call this topic was discussed and add some further color?